Clinical Trial Update: Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, immunogenicity and tolerability of a meningococcal group B vaccine in healthy adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Meningitis

Drugs mentioned

• Meningococcal group B vaccine (Neisseria meningitidis serogroup B vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Meningitis, Meningococcal | Phase 1 | Status: COMPLETED